Expression of LAG-3, TIM-3, and VISTA on Tumor-Infiltrating Lymphocytes in Advanced Laryngeal Squamous Cell Carcinoma and Their Association with CD8+ TIL Density
Open Access
- 15 July 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1587
Abstract
Background: Alternative immune checkpoints such as lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain-containing-3 (TIM-3), and V-domain Ig suppressor of T-cell activation (VISTA) have emerged as potential modulators of tumor immune escape. However, their expression patterns and prognostic significance in advanced laryngeal squamous cell carcinoma (LSCC) remain insufficiently characterized. This study aimed to evaluate LAG-3, TIM-3, and VISTA expression on tumor-infiltrating lymphocytes (TILs), examine their association with CD8+ TIL density and clinicopathological features, and determine their impact on survival outcomes. Methods: In this retrospective observational cohort study, 132 patients who underwent total or partial laryngectomy for stage III–IV LSCC were included. Tissue microarrays were constructed using three 2 mm cores per case. Immunohistochemical expression of LAG-3, TIM-3, VISTA, and CD8 was assessed exclusively on TILs. Survival outcomes were analyzed using Kaplan–Meier and Cox proportional hazards models. Results: LAG-3, TIM-3, and VISTA positivity rates were 26.5%, 51.5%, and 53.8%, respectively. High CD8+ TIL density was observed in 69.7% of cases. Significant positive correlations were identified among checkpoint markers (all p < 0.05); VISTA positivity did not significantly correlate with CD8 infiltration (r = 0.149, p = 0.088). LAG-3 positivity was associated with lower thyroid cartilage invasion (p = 0.006). Kaplan–Meier analysis demonstrated no significant differences in overall survival (OS) or disease-free survival (DFS) according to checkpoint expression or CD8 status. In multivariable analysis, extranodal extension (HR = 2.719, p = 0.005) and thyroid cartilage invasion (HR = 1.970, p = 0.043) were independent predictors of worse OS. CD8 negativity showed a trend toward adverse OS (HR = 1.825, p = 0.084). None of the immune markers independently predicted DFS. Conclusions: In advanced surgically treated LSCC, LAG-3, TIM-3, and VISTA expression correlate with CD8+ TIL density but do not independently predict survival outcomes. These findings suggest that alternative immune checkpoint expression reflects immune engagement rather than intrinsic tumor aggressiveness and may hold greater predictive than prognostic relevance in LSCC.Keywords
Funding Information
- Adnan Menderes Üniversitesi (TPF-23013)
This publication has 49 references indexed in Scilit:
- Extranodal extension in laryngeal squamous cell carcinomaLaryngoscope Investigative Otolaryngology, 2024
- Significance of TIM-3 Expression in Resected Esophageal Squamous Cell CarcinomaThe Annals of Thoracic Surgery, 2020
- Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 ExpressionHead and Neck Pathology, 2020
- VISTA: A novel immunotherapy target for normalizing innate and adaptive immunitySeminars in Immunology, 2019
- T Cell Dysfunction in CancerCancer Cell, 2018
- Tim-3, Lag-3, and TIGIT2017
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating LymphocytesJournal of Thoracic Oncology, 2017
- Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinomaCancer Immunology, Immunotherapy, 2017
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Prognostic versus predictive value of biomarkers in oncologyEuropean Journal of Cancer, 2008